TSFLAB04b:	Subjects With [Last/Any] On-treatment Hematology Values [= Level 2] Criteria; Safety Analysis Set (Study jjcs - core)						
 	Active Study Agent 	Active Study Agent 	 	Risk Difference (%) (95% CI) 	Risk Difference (%) (95% CI) 	
Laboratory Category 	Xanomeline High Dose 	Xanomeline Low Dose 	Placebo 	Xanomeline High Dose vs Placebo 	Xanomeline Low Dose vs Placebo 	
  Laboratory Test ≥ Level 2, n (%) 	N=53 	N=73 	N=59 	  	  	
Complete blood count 	 	 	 	 	 	
Hemoglobin, male (<125 g/L) 	47/53 (88.7%) 	54/71 (76.1%) 	53/59 (89.8%) 	-1.2 (-12.7, 10.3) 	-13.8 (-26.3, -1.2) 	

Note: On-treatment is defined as treatment-emergent laboratory values obtained after the first dose and within [30 days] following treatment discontinuation. [Treatment-emergent values are those that worsened from baseline.] 	
Note: On-treatment is defined as treatment-emergent laboratory values obtained after the first dose and within [30 days] following treatment discontinuation. [Treatment-emergent values are those that worsened from baseline.]	
Note: On-treatment is defined as treatment-emergent laboratory values obtained after the first dose and within [30 days] following treatment discontinuation. [Treatment-emergent values are those that worsened from baseline.]	
Note: On-treatment is defined as treatment-emergent laboratory values obtained after the first dose and within [30 days] following treatment discontinuation. [Treatment-emergent values are those that worsened from baseline.]	
Note: On-treatment is defined as treatment-emergent laboratory values obtained after the first dose and within [30 days] following treatment discontinuation. [Treatment-emergent values are those that worsened from baseline.]	
Note: On-treatment is defined as treatment-emergent laboratory values obtained after the first dose and within [30 days] following treatment discontinuation. [Treatment-emergent values are those that worsened from baseline.]